<DOC>
	<DOCNO>NCT00589901</DOCNO>
	<brief_summary>The primary objective study evaluate time progression . Secondary objective safety , OS pharmacogenetic analysis . Sixty patient enrol study .</brief_summary>
	<brief_title>An All-Oral Combination Capecitabine Cyclophosphamide Patients With Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>Xeloda ( capecitabine ) convert 5-fluorouracil thymidine phosphorylase , cyclophosphamide capable upregulating expression thymidine phosphorylase suggest synergistic effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically confirm breast cancer Anthracycline taxane pretreated metastatic breast cancer Have previously treat capecitabine ECOG performance status ≤ 1 Are female ≥ 18 ≤ 70 year age Have least one target lesion accord RECIST criterion Pregnant lactate woman ECOG ≥ 2 Have treat capecitabine Evidence CNS metastasis History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix contralateral breast cancer Abnormal laboratory value : hemoglobin &lt; 8.0 g/dl , neutrophils &lt; 1.5×10^9/L , platelet &lt; 100×10^9/L , serum creatinine &gt; upper limit normal ( ULN ) , serum bilirubin &gt; ULN , ALT AST &gt; 5×ULN , AKP &gt; 5×ULN Serious uncontrolled intercurrent infection Life expectancy le 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>synergistic effect</keyword>
	<keyword>chemotherapy</keyword>
</DOC>